Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to -$18.6 million.

  • Lineage Cell Therapeutics' Net Income towards Common Stockholders fell 13.96% to -$3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.0 million, marking a year-over-year decrease of 59.75%. This contributed to the annual value of -$18.6 million for FY2024, which is 13.49% up from last year.
  • Lineage Cell Therapeutics' Net Income towards Common Stockholders amounted to -$18.6 million in FY2024, which was up 13.49% from -$21.5 million recorded in FY2023.
  • Lineage Cell Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$18.6 million during FY2024, with a 5-year trough of -$43.3 million in FY2021.
  • In the last 3 years, Lineage Cell Therapeutics' Net Income towards Common Stockholders had a median value of -$21.5 million in 2023 and averaged -$22.1 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first plummeted by 109.19% in 2021, then soared by 39.10% in 2022.
  • Lineage Cell Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$20.7 million in 2020, then tumbled by 109.19% to -$43.3 million in 2021, then spiked by 39.10% to -$26.4 million in 2022, then climbed by 18.50% to -$21.5 million in 2023, then grew by 13.49% to -$18.6 million in 2024.